pSivida Corp. PSDV today announced that its licensee
Alimera Sciences, Inc. has received a Complete Response Letter (CRL) for
the New Drug Application (NDA) for ILUVIEN® from the U.S. Food and Drug
Administration (FDA).
Identifying concerns regarding the benefit to risk and safety profiles
of ILUVIEN, the FDA stated that the NDA could not be approved in its
present form. To address the clinical and statistical deficiencies
identified, the FDA indicated that results from a new clinical trial
would need to be submitted, together with at least 12 months of
follow-up for all enrolled
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in